Last year, Bristol-Myers Squibb Co generated 14.44B USD for its biggest-performing segment, Eliquis. The United States made the largest contribution, accounting for 33.28B USD last year. For the latest quarter, Bristol-Myers Squibb Co reported the revenue of 4.48B USD for the period ending 2026-06-30, which came from the top-performing segment, Eliquis. United States contributed the highest revenue, at 8.99B USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Eliquis

Opdivo

Orencia

Revlimid

Yervoy

Pomalyst/Imnovid

Other

Reblozyl

Breyanzi

Opdualag

Camzyos

Zeposia

Sprycel

Abecma

Abraxane

Sotyktu

Krazati

Cobenfy

Other

Abecma

Augtyro

Onureg

Inrebic

Empliciti

Established Brands-Vidaza

Established Brands-Baraclude

Established Brands-Reyataz Franchise

Established Brands-Sustiva Franchise

Established Brands-Hepatitis C Franchise

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Eliquis

14.44B(29.97%)

13.33B(27.55%)

12.21B(27.12%)

11.79B(25.54%)

10.76B(23.20%)

9.17B(21.56%)

7.93B(30.33%)

6.44B(28.54%)

Opdivo

10.29B(21.34%)

9.30B(19.23%)

9.01B(20.02%)

8.25B(17.87%)

7.52B(16.22%)

6.99B(16.44%)

7.20B(27.55%)

6.74B(29.85%)

Orencia

3.71B(7.69%)

3.68B(7.61%)

3.60B(8.00%)

3.46B(7.50%)

3.31B(7.13%)

3.16B(7.43%)

2.98B(11.39%)

2.71B(12.01%)

Revlimid

2.95B(6.12%)

5.77B(11.93%)

6.10B(13.55%)

9.98B(21.62%)

12.82B(27.64%)

12.11B(28.47%)

1.30B(4.97%)

--(--)

Yervoy

2.90B(6.02%)

2.53B(5.23%)

2.24B(4.97%)

2.13B(4.62%)

2.03B(4.37%)

1.68B(3.96%)

1.49B(5.70%)

1.33B(5.90%)

Pomalyst/Imnovid

2.73B(5.67%)

3.54B(7.33%)

3.44B(7.65%)

3.50B(7.58%)

3.33B(7.18%)

3.07B(7.22%)

322.00M(1.23%)

--(--)

Other

2.72B(5.65%)

--(--)

Reblozyl

2.33B(4.83%)

1.77B(3.66%)

1.01B(2.24%)

717.00M(1.55%)

551.00M(1.19%)

274.00M(0.64%)

--(--)

Breyanzi

1.36B(2.82%)

747.00M(1.54%)

364.00M(0.81%)

182.00M(0.39%)

87.00M(0.19%)

--(--)

Opdualag

1.19B(2.46%)

928.00M(1.92%)

627.00M(1.39%)

252.00M(0.55%)

--(--)

Camzyos

1.07B(2.21%)

284.00M(0.59%)

231.00M(0.51%)

24.00M(0.05%)

--(--)

Zeposia

578.00M(1.20%)

566.00M(1.17%)

434.00M(0.96%)

250.00M(0.54%)

134.00M(0.29%)

12.00M(0.03%)

--(--)

Sprycel

493.00M(1.02%)

1.29B(2.66%)

1.93B(4.29%)

2.17B(4.69%)

2.12B(4.56%)

2.14B(5.03%)

2.11B(8.07%)

2.00B(8.86%)

Abecma

427.00M(0.89%)

406.00M(0.84%)

--(--)

Abraxane

367.00M(0.76%)

875.00M(1.81%)

1.00B(2.23%)

811.00M(1.76%)

1.18B(2.55%)

1.25B(2.93%)

166.00M(0.63%)

--(--)

Sotyktu

292.00M(0.61%)

246.00M(0.51%)

170.00M(0.38%)

8.00M(0.02%)

--(--)

Krazati

205.00M(0.43%)

126.00M(0.26%)

--(--)

Cobenfy

155.00M(0.32%)

10.00M(0.02%)

--(--)

Other

--(--)

2.53B(5.23%)

1.90B(4.21%)

1.75B(3.79%)

1.90B(4.10%)

1.31B(3.09%)

1.67B(6.40%)

1.63B(7.22%)

Abecma

--(--)

406.00M(0.84%)

472.00M(1.05%)

388.00M(0.84%)

164.00M(0.35%)

--(--)

Augtyro

--(--)

38.00M(0.08%)

1.00M(--)

--(--)

Onureg

--(--)

168.00M(0.37%)

124.00M(0.27%)

73.00M(0.16%)

17.00M(0.04%)

--(--)

Inrebic

--(--)

110.00M(0.24%)

85.00M(0.18%)

74.00M(0.16%)

55.00M(0.13%)

5.00M(0.02%)

--(--)

Empliciti

--(--)

296.00M(0.64%)

334.00M(0.72%)

381.00M(0.90%)

357.00M(1.37%)

247.00M(1.09%)

Established Brands-Vidaza

--(--)

455.00M(1.07%)

58.00M(0.22%)

--(--)

Established Brands-Baraclude

--(--)

447.00M(1.05%)

555.00M(2.12%)

744.00M(3.30%)

Established Brands-Reyataz Franchise

--(--)

427.00M(1.89%)

Established Brands-Sustiva Franchise

--(--)

283.00M(1.25%)

Established Brands-Hepatitis C Franchise

--(--)

17.00M(0.08%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

International

other

Rest of the World

Europe

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

33.28B(69.05%)

34.10B(70.61%)

31.55B(70.11%)

31.83B(68.95%)

29.21B(62.98%)

26.58B(62.51%)

15.34B(58.68%)

International

13.83B(28.69%)

13.20B(27.33%)

12.75B(28.33%)

--(--)

other

1.09B(2.26%)

996.00M(2.06%)

699.00M(1.55%)

834.00M(1.81%)

852.00M(1.84%)

631.00M(1.48%)

524.00M(2.00%)

Rest of the World

--(--)

13.50B(29.24%)

5.63B(12.14%)

5.46B(12.83%)

4.01B(15.35%)

Europe

--(--)

10.69B(23.04%)

9.85B(23.17%)

6.27B(23.97%)